- Drugged driving fatalities continue to rise in the US, with a particular surge in marijuana, opioids, and stimulants.
- Federal efforts to address the crisis have stalled, despite mounting evidence of the danger and knowledge gap.
- The legalization of marijuana in over 20 states and the ongoing opioid crisis are driving the rise in drugged driving.
- There is no widely accepted measure of drug impairment, making it difficult to determine when a driver was impaired at the time of a crash.
- The lack of standardized testing and national policy has led to a dangerous knowledge and enforcement gap.
How can the United States address a growing wave of drugged driving if it won’t study the problem? That is the question confronting public health experts, law enforcement officials, and transportation agencies as fatalities involving drivers under the influence of drugs—particularly marijuana, opioids, and stimulants—continue to climb. Two state transportation workers replacing a sign on U.S. Highway 6 in western Colorado were struck and killed in 2019 when a driver operating a Jeep Grand Cherokee veered off the road. The driver tested positive for THC, the active compound in marijuana. This tragedy is not isolated. Yet, despite mounting evidence of the danger, federal efforts to collect comprehensive data, standardize testing, and develop national policy have largely stalled, especially during the Trump administration, leaving a dangerous knowledge and enforcement gap.
What Is Behind the Drugged Driving Surge?
The rise in drugged driving is closely tied to shifting drug use patterns, the legalization of marijuana in over 20 states, and the ongoing opioid crisis. Unlike alcohol, where blood alcohol concentration (BAC) provides a reliable and standardized measure of impairment, there is no widely accepted equivalent for drugs. THC, for example, can remain in a person’s system for days or weeks after use, making it difficult to determine when—or even if—a driver was impaired at the time of a crash. Federal agencies like the National Highway Traffic Safety Administration (NHTSA) have historically focused on alcohol-impaired driving, which has seen significant reductions over the past decades due to coordinated public health campaigns and strict legal limits. However, efforts to expand that framework to drug-impaired driving slowed notably during the Trump administration, as funding for research was deprioritized and key data collection programs saw reduced support.
What Does the Data Reveal About Impaired Driving?
Despite limited federal oversight, available data paints a concerning picture. According to NHTSA’s most recent National Roadside Survey, the prevalence of drugs other than alcohol in drivers has more than doubled since 2007. In fatal crashes, nearly 44% of drivers tested positive for at least one psychoactive substance in 2019, up from 27% in 2007, with THC detected in 22% of cases. A 2021 report by the Governors Highway Safety Association warned that drugged driving is an emerging national threat exacerbated by inconsistent state laws, lack of reliable roadside testing, and insufficient training for law enforcement. Some experts argue that correlation does not equal causation—testing positive for a drug does not necessarily mean the driver was impaired. However, studies published in scientific journals like Accident Analysis & Prevention have shown that drivers with THC in their system are significantly more likely to be involved in crashes, particularly when combined with alcohol.
What Do Skeptics and Experts Disagree On?
Not all experts agree on how to interpret the data or what policy responses are appropriate. Some toxicologists and civil liberties advocates caution against equating drug presence with impairment, warning that overreliance on drug tests could lead to wrongful convictions or racial profiling, especially given disparities in drug enforcement. They argue that behavioral assessments—such as field sobriety tests and drug recognition evaluations—should carry more weight than chemical tests alone. Others point out that many people use marijuana responsibly and drive without incident. Additionally, the absence of a federal standard for drug impairment creates a patchwork of state laws: some states have “per se” laws that criminalize driving with any detectable amount of THC, while others require proof of active impairment. This inconsistency makes it difficult to compare data across states or develop cohesive national strategies.
What Are the Real-World Consequences of Inaction?
The lack of federal leadership has real consequences. States are left to develop their own approaches with limited resources. Colorado, one of the first states to legalize recreational marijuana, has invested in public awareness campaigns and trained hundreds of drug recognition experts, but still struggles with rising crash rates involving impaired drivers. In contrast, states without robust training or testing infrastructure often fail to detect drug-impaired driving altogether, leading to underreporting. Families of victims, like those of the two workers killed on Highway 6, say the justice system fails to hold drugged drivers accountable due to legal loopholes and evidentiary challenges. Moreover, without standardized data, vehicle manufacturers and safety researchers cannot effectively design technologies to detect or prevent drug-impaired driving, putting all road users at greater risk.
What This Means For You
If you drive, you share the road with others who may be impaired by drugs, and current laws and enforcement may not be equipped to stop them. As marijuana use becomes more common and accepted, understanding the difference between legal use and unsafe driving is crucial. Support for better roadside testing, more training for law enforcement, and public education can help close the gap in safety. While alcohol impairment is widely recognized and stigmatized, drugged driving still lacks the same cultural and legal clarity—putting lives at risk.
Can the U.S. develop a fair, science-based system for identifying and preventing drugged driving before more lives are lost? And will future administrations prioritize research and policy to catch up with the nation’s evolving drug landscape?
Source: MedicalXpress